# Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

> **NCT07386704** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Peking University First Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Cancer Non-resectable

## Interventions

- **DRUG:** Nimotuzumab combined with chemoradiotherapy

## Key facts

- **NCT ID:** NCT07386704
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-12-09
- **Primary completion:** 2026-12-09
- **Final completion:** 2027-12-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07386704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07386704, "Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07386704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*